Red Yeast Rice Interactions

Red yeast rice contains monacolin K, which is chemically identical to the statin lovastatin. Taking red yeast rice together with prescription lovastatin means taking the same statin twice, adding to HMG-CoA reductase inhibition and raising the risk of muscle injury (including rhabdomyolysis) and liver harm. Because the amount of monacolin K in red yeast rice is variable and usually not stated on the label, the added statin exposure is unpredictable and stacks on top of an already-active prescription dose.

Seville orange contains furanocoumarins that inhibit intestinal CYP3A4, the enzyme that clears the monacolin K in red yeast rice. Because monacolin K is chemically identical to the statin lovastatin and depends on CYP3A4 for its first-pass breakdown, blocking that enzyme raises systemic exposure to the active statin, increasing the risk of muscle-related side effects such as myopathy and, rarely, rhabdomyolysis.

Pomelo, like grapefruit, contains furanocoumarins that inhibit the intestinal CYP3A4 enzyme. Red yeast rice's active constituent, monacolin K, is chemically identical to the statin lovastatin, which depends on CYP3A4 for its breakdown. When pomelo blocks that enzyme, more of the monacolin K reaches the bloodstream, amplifying the dose-dependent statin-type risks of muscle injury and, rarely, liver enzyme elevation. Because furanocoumarin inhibition can persist for days, the effect is not reliably avoided by taking the two at different times of day.

Clarithromycin is a strong CYP3A4 inhibitor. Red yeast rice's active compound, monacolin K, is chemically identical to the statin lovastatin and is cleared mainly by CYP3A4. Combining them slows clearance of the statin-like compound and raises its blood levels, increasing the risk of muscle injury and, rarely, rhabdomyolysis.

Red yeast rice supplies monacolin K, a compound chemically identical to the statin lovastatin. Combining it with gemfibrozil, a fibrate, can add up to serious muscle injury. The fibrate is itself toxic to muscle and also raises circulating statin levels by interfering with how the statin is cleared, so the two effects stack toward myopathy and, in the worst case, rhabdomyolysis with kidney injury.

Grapefruit inhibits intestinal CYP3A4, the enzyme that clears red yeast rice's active constituent monacolin K (the same molecule as the statin lovastatin). Blocking this enzyme lets more monacolin K reach the bloodstream, raising its cholesterol-enzyme-blocking activity and the associated risk of muscle-related side effects. This is a food-drug interaction driven by the grapefruit inhibitor, and because some unregulated red yeast rice products carry near-prescription statin content, the risk can be meaningful.

Red yeast rice contains monacolin K, which is chemically identical to the prescription statin lovastatin. Adding it to simvastatin stacks two statins with the same mechanism and metabolism, adding to the risk of muscle injury, rhabdomyolysis, and liver problems.

Red yeast rice naturally contains monacolin K, the same compound as the prescription statin lovastatin. Taking it alongside atorvastatin effectively stacks two statins working through the same liver pathway, raising the risk of statin-associated muscle symptoms, rhabdomyolysis, and liver injury.

Red yeast rice contains monacolin K, chemically the same as a statin, which carries a small, uncommon risk of liver injury. Alcohol is also hard on the liver, so combining the two — especially heavy or regular drinking — can add to the strain on the same organ.

Red yeast rice contains monacolin K, which is chemically identical to the statin lovastatin, so it behaves as a low-dose statin. Lipid-modifying amounts of niacin can independently injure skeletal muscle, and combining a lovastatin-class agent with such niacin can add to the risk of muscle pain or damage (including, rarely, rhabdomyolysis). Because red yeast rice acts as a variable-strength statin, the same additive muscle-toxicity concern applies when it is taken alongside high-dose niacin.

Red yeast rice contains monacolin K, a compound chemically identical to a statin, so taking it alongside rosuvastatin stacks a second statin-like HMG-CoA reductase inhibitor on top of the prescription statin. Because rosuvastatin is not broken down by the CYP3A4 enzyme, there is no enzyme-based (pharmacokinetic) interaction; the concern is purely additive statin-class exposure. This modestly raises the combined potential for statin-type muscle injury (myopathy, and rarely rhabdomyolysis) and liver injury beyond either agent alone. The added statin burden is usually small because red yeast rice's monacolin content is typically low, highly variable, and not shown on the label, but unregulated high-monacolin products can carry a more meaningful statin-like load.

St. John's wort is a strong inducer of the CYP3A4 enzyme system that clears the statin-like compound (monacolin K, chemically identical to lovastatin) in red yeast rice. Taking them together speeds up how the body breaks down that compound, lowering its levels and weakening red yeast rice's cholesterol-lowering effect. The concern here is loss of benefit rather than toxicity, and the direction is the opposite of CYP3A4-inhibitor interactions, so it does not raise muscle-injury risk.

Soluble, viscous fibers like oat fiber can bind and slow the absorption of the statin-like compound (monacolin K) in red yeast rice when the two are taken together. Because monacolin K is chemically identical to prescription lovastatin, the documented effect of pectin and oat bran on lovastatin absorption applies directly: co-ingested soluble fiber can reduce how much of the active statin reaches the bloodstream, blunting red yeast rice's cholesterol-lowering effect. The effect is about lost benefit rather than a safety hazard, and it is reversible when the two are separated in time.

Red yeast rice contains monacolin K, a compound chemically identical to the statin lovastatin. Taking it alongside pravastatin means two HMG-CoA reductase inhibitors are active at the same time, so their cholesterol-lowering statin effect and their potential for muscle injury (muscle pain, and rarely rhabdomyolysis) add together. Because pravastatin is water-soluble and is not broken down by the CYP3A4 enzyme, this is not a metabolic (drug-processing) interaction — it is simply the additive effect of stacking two statin-type ingredients, made harder to gauge by red yeast rice's variable, unlabeled monacolin content.

Berberine and red yeast rice are frequently combined in cholesterol-lowering nutraceuticals and act through complementary routes: berberine upregulates hepatic LDL receptors and reduces lipogenesis, while red yeast rice's monacolin K (chemically identical to lovastatin) inhibits HMG-CoA reductase. Together they produce additive LDL reduction. Secondarily, berberine mildly inhibits CYP3A4, the enzyme that clears lovastatin/monacolin K, so it can modestly raise monacolin K exposure and add to statin-type muscle risk. In practice the pairing is generally well tolerated because red yeast rice delivers only a low, variable, unregulated monacolin dose, so the additive muscle/CYP3A4 concern sits at the low end and the intended lipid-lowering synergy dominates.

Red yeast rice's active constituent monacolin K is chemically identical to the statin lovastatin and inhibits HMG-CoA reductase, the shared enzyme step upstream of both cholesterol and coenzyme Q10 (ubiquinone). Statin therapy measurably lowers circulating CoQ10, and CoQ10 depletion is one proposed contributor to statin-type muscle symptoms. Co-taking a CoQ10 supplement replenishes that pool and may help ease statin-type muscle complaints without reducing red yeast rice's cholesterol-lowering effect. This is a complementary, potentially beneficial pairing rather than a harmful conflict.